Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant sex » significant gap (Expand Search), significant _ (Expand Search), significant cause (Expand Search)
sex decrease » step decrease (Expand Search), we decrease (Expand Search), sizes decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant sex » significant gap (Expand Search), significant _ (Expand Search), significant cause (Expand Search)
sex decrease » step decrease (Expand Search), we decrease (Expand Search), sizes decrease (Expand Search)
-
561
-
562
-
563
-
564
-
565
-
566
-
567
-
568
-
569
-
570
Recruitment flow diagram of the current study.
Published 2025“…Phase 1 EQ-VAS decreases were associated with female sex, lower somatic symptom, fewer comorbidities, lack of expectation for a fast recovery, higher ISS, higher injury pain, neck, spine/back or lower extremity injuries. …”
-
571
-
572
Baseline characteristics of mother–infant pairs by child mortality status (N = 11,519).
Published 2025Subjects: -
573
Child mortality rate per 1,000 person-years during the 18-month follow-up period.
Published 2025Subjects: -
574
Kaplan–Meier cumulative survival curve for infants exposed and not exposed to HIV.
Published 2025Subjects: -
575
-
576
-
577
-
578
-
579
Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i>
Published 2025“…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P<sub>i</sub>‐induced VSMCs. …”
-
580